The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study

Rheumatology

Volumn 44, Issue 4, 2005, Pages 472-478

  Flendrie, M ^a   Creemers, M C W ^a   Welsing, P M J ^a   van Riel, P L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Infliximab; Leflunomide; Rheumatoid arthisis; Therapy

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; SULFALAZINE; ANTIRHEUMATIC AGENT; ISOXAZOLE DERIVATIVE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APPENDIX PERFORATION; ARTHRITIS; ARTICLE; BREAST CARCINOMA; CARDIOVASCULAR DISEASE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEMYELINATING DISEASE; DIABETES MELLITUS; DISEASE ACTIVITY; DISKITIS; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG INFUSION REACTION; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GINGIVA HYPERPLASIA; HEADACHE; HEART INFARCTION; HUMAN; INFECTION; LEG ULCER; LEUKEMOID REACTION; LEUKOPENIA; LONGITUDINAL STUDY; LUNG DISEASE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MYALGIA; NERVE ROOT COMPRESSION; NEUROLOGIC DISEASE; OPTIC NERVE DISEASE; PATIENT CODING; PERIPHERAL NEUROPATHY; PNEUMONIA; POLYMYOSITIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEPSIS; SKIN DISEASE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; VERTEBRAL CANAL STENOSIS; BLOOD; DRUG ADMINISTRATION; DRUG COMBINATION; EPIDEMIOLOGY; HOSPITALIZATION; IMMUNOLOGY; MIDDLE AGED;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 18744408791     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh508     Document Type: Article

References (23)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:269-81.
2. Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995;38:1595-603.
3. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66.
4. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
5. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
6. Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacv of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44.
7. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003; 48:35-45.
8. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventive strategy. Ann Intern Med 1999;131:768-74.
9. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
10. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
11. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
12. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46.
13. Godinho F, Godfrin B, El Mahou S, Navaux F, Zabraniecki L, Cantagrel A. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatol 2004;22:328-30.
14. Hansen KE, Cush J, Singhal A, et al. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum 2004;51:228-32.
15. Kiely PD, Johnson DM. Infliximab and leflunomide combination therapy in rheumatoid arthritis: An open-label study. Rheumatology 2002;41:631-7.
16. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
18. van der Heijde DM, van't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992;51:177-81.
19. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
20. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002;41:421-30.
21. Bingham S, Barcelos A, Buch MH, Lindsay S, Emery P. Induction of serological lupus in patients on leflunomide and infliximab (abstract). Arthritis Rheum 2002;46:S168.
22. Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha - Findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
23. Louis M, Rauch J, Armstrong M, Fitzcharles MA. Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 2003;30:2557-62.